Pharmaceuticals · NYSE: AZN
AstraZeneca earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 9 Feb 2027
Latest: Q3 2026
AstraZeneca is pairing its antibody-drug conjugates with Summit's ivonescimab via a $2bn equity stake, while 12 positive Phase III readouts widen its late-stage pipeline.
Demand is broad across cancer, respiratory and rare disease. Imfinzi, Enhertu, Tezspire and Ultomiris keep widening into earlier treatment settings, and four new medicines won their first approvals, including Etcamah and Baxfendy. The Baxfendy hypertension launch has reached 12,000 new patient starts, mostly in commercial plans. Tagrisso is being extended with Orpathys, and Datroway is gaining ground in breast and lung cancer. Farxiga and Brilinta generic competition is the main drag.
Quarters
KPI history
20-F filings
- 24 Feb 202620-F for the period ended 31 Dec 2025SEC ↗
- 18 Feb 202520-F for the period ended 31 Dec 2024SEC ↗
- 20 Feb 202420-F for the period ended 31 Dec 2023SEC ↗
- 21 Feb 202320-F for the period ended 31 Dec 2022SEC ↗
- 22 Feb 202220-F for the period ended 31 Dec 2021SEC ↗
- 16 Feb 202120-F for the period ended 31 Dec 2020SEC ↗
- 3 Mar 202020-F for the period ended 31 Dec 2019SEC ↗